PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17031857-0 2007 (--)-epigallocatechin gallate enhances prostaglandin F2alpha-induced VEGF synthesis via upregulating SAPK/JNK activation in osteoblasts. Dinoprost 39-60 vascular endothelial growth factor A Mus musculus 69-73 22614766-2 2012 We have previously shown that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) via mitogen-activated protein (MAP) kinases, including p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) in osteoblast-like MC3T3-E1 cells. Dinoprost 30-51 vascular endothelial growth factor A Mus musculus 92-126 22614766-2 2012 We have previously shown that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) via mitogen-activated protein (MAP) kinases, including p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) in osteoblast-like MC3T3-E1 cells. Dinoprost 30-51 vascular endothelial growth factor A Mus musculus 128-132 22614766-2 2012 We have previously shown that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) via mitogen-activated protein (MAP) kinases, including p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) in osteoblast-like MC3T3-E1 cells. Dinoprost 53-62 vascular endothelial growth factor A Mus musculus 92-126 22614766-2 2012 We have previously shown that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) via mitogen-activated protein (MAP) kinases, including p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) in osteoblast-like MC3T3-E1 cells. Dinoprost 53-62 vascular endothelial growth factor A Mus musculus 128-132 22614766-3 2012 In the present study, we investigated the effects of Wnt3a on the synthesis of VEGF or IL-6 stimulated by PGF2alpha in MC3T3-E1 cells using an ELISA kit and various antibodies. Dinoprost 106-115 vascular endothelial growth factor A Mus musculus 79-83 22614766-5 2012 Wnt3a significantly enhanced the PGF2alpha-stimulated VEGF release but had little effect on the PGF2alpha-stimulated IL-6 release. Dinoprost 33-42 vascular endothelial growth factor A Mus musculus 54-58 22614766-6 2012 SB216763 markedly amplified the PGF2alpha-stimulated VEGF release without affecting the IL-6 release, similar to Wnt3a. Dinoprost 32-41 vascular endothelial growth factor A Mus musculus 53-57 22614766-8 2012 These results strongly suggest that Wnt3a upregulates VEGF synthesis stimulated by PGF2alpha via activation of the canonical pathway in osteoblasts without affecting IL-6 synthesis. Dinoprost 83-92 vascular endothelial growth factor A Mus musculus 54-58 33478532-0 2021 HSP22 (HSPB8) positively regulates PGF2alpha-induced synthesis of interleukin-6 and vascular endothelial growth factor in osteoblasts. Dinoprost 35-44 vascular endothelial growth factor A Mus musculus 84-118 33478532-2 2021 We previously demonstrated that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling factor, induces the synthesis of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells. Dinoprost 32-53 vascular endothelial growth factor A Mus musculus 150-184 33478532-2 2021 We previously demonstrated that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling factor, induces the synthesis of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells. Dinoprost 32-53 vascular endothelial growth factor A Mus musculus 186-190 33478532-2 2021 We previously demonstrated that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling factor, induces the synthesis of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells. Dinoprost 55-64 vascular endothelial growth factor A Mus musculus 150-184 33478532-2 2021 We previously demonstrated that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling factor, induces the synthesis of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells. Dinoprost 55-64 vascular endothelial growth factor A Mus musculus 186-190 33478532-3 2021 In the present study, we investigated whether HSP22 is implicated in the PGF2alpha-induced synthesis of IL-6 and VEGF and the mechanism of MC3T3-E1 cells. Dinoprost 73-82 vascular endothelial growth factor A Mus musculus 113-117 33478532-8 2021 HSP22 knockdown also reduced the VEGF release by PGF2alpha. Dinoprost 49-58 vascular endothelial growth factor A Mus musculus 33-37 33478532-10 2021 CONCLUSIONS: Our results strongly suggest that HSP22 acts as a positive regulator in the PGF2alpha-induced synthesis of IL-6 and VEGF in osteoblasts. Dinoprost 89-98 vascular endothelial growth factor A Mus musculus 129-133 17980568-0 2007 Platelet-derived growth factor-BB amplifies PGF2alpha-stimulated VEGF synthesis in osteoblasts: function of phosphatidylinositol 3-kinase. Dinoprost 44-53 vascular endothelial growth factor A Mus musculus 65-69 17980568-1 2007 We have reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase in osteoblast-like MC3T3-E1 cells. Dinoprost 22-43 vascular endothelial growth factor A Mus musculus 84-118 17980568-1 2007 We have reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase in osteoblast-like MC3T3-E1 cells. Dinoprost 22-43 vascular endothelial growth factor A Mus musculus 120-124 17980568-1 2007 We have reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase in osteoblast-like MC3T3-E1 cells. Dinoprost 45-54 vascular endothelial growth factor A Mus musculus 84-118 17980568-1 2007 We have reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase in osteoblast-like MC3T3-E1 cells. Dinoprost 45-54 vascular endothelial growth factor A Mus musculus 120-124 17980568-3 2007 In the present study, we investigated the effect of PDGF-BB on the PGF2alpha-induced VEGF synthesis in MC3T3-E1 cells. Dinoprost 67-76 vascular endothelial growth factor A Mus musculus 85-89 17980568-4 2007 PDGF-BB, which alone did not affect the levels of VEGF, significantly enhanced the PGF2alpha-stimulated VEGF synthesis. Dinoprost 83-92 vascular endothelial growth factor A Mus musculus 104-108 17980568-7 2007 PD98059, a specific inhibitor of MEK1/2, suppressed the amplification by PDGF-BB of the PGF2alpha-stimulated VEGF synthesis similar to the levels of PGF2alpha with PD98059. Dinoprost 88-97 vascular endothelial growth factor A Mus musculus 109-113 17980568-10 2007 These results strongly suggest that PGF2alpha-stimulated VEGF synthesis is amplified by PI3-kinase-mediating PDGF-BB signaling in osteoblasts, and that the effect is exerted at a point downstream from p44/p42 MAP kinase. Dinoprost 36-45 vascular endothelial growth factor A Mus musculus 57-61 15922088-9 2005 These results strongly suggest that tiludronate but not etidronate suppresses the PGF2alpha-stimulated VEGF synthesis in osteoblasts, and that the effect of tiludronate is exerted at the point between PKC and Raf-1. Dinoprost 82-91 vascular endothelial growth factor A Mus musculus 103-107 16673205-0 2006 Minodronate suppresses prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Dinoprost 23-44 vascular endothelial growth factor A Mus musculus 53-87 16673205-1 2006 In our previous study, we showed that prostaglandin F2alpha (PGF2alpha) stimulates vascular endothelial growth factor (VEGF) synthesis via activation of p44/p42 mitogen-activated protein (MAP) kinase via protein kinase C (PKC) in osteoblast-like MC3T3-E1 cells. Dinoprost 38-59 vascular endothelial growth factor A Mus musculus 83-117 16673205-1 2006 In our previous study, we showed that prostaglandin F2alpha (PGF2alpha) stimulates vascular endothelial growth factor (VEGF) synthesis via activation of p44/p42 mitogen-activated protein (MAP) kinase via protein kinase C (PKC) in osteoblast-like MC3T3-E1 cells. Dinoprost 38-59 vascular endothelial growth factor A Mus musculus 119-123 16673205-1 2006 In our previous study, we showed that prostaglandin F2alpha (PGF2alpha) stimulates vascular endothelial growth factor (VEGF) synthesis via activation of p44/p42 mitogen-activated protein (MAP) kinase via protein kinase C (PKC) in osteoblast-like MC3T3-E1 cells. Dinoprost 61-70 vascular endothelial growth factor A Mus musculus 83-117 16673205-1 2006 In our previous study, we showed that prostaglandin F2alpha (PGF2alpha) stimulates vascular endothelial growth factor (VEGF) synthesis via activation of p44/p42 mitogen-activated protein (MAP) kinase via protein kinase C (PKC) in osteoblast-like MC3T3-E1 cells. Dinoprost 61-70 vascular endothelial growth factor A Mus musculus 119-123 16673205-2 2006 In addition, we demonstrated that incadronate amplified, and tiludronate suppressed PGF2alpha-induced VEGF synthesis among bisphosphonates, while alendronate or etidronate had no effect. Dinoprost 84-93 vascular endothelial growth factor A Mus musculus 102-106 16673205-4 2006 Minodronate significantly reduced VEGF synthesis induced by PGF2alpha dose-dependently at levels between 3 and 100 microM. Dinoprost 60-69 vascular endothelial growth factor A Mus musculus 34-38 16673205-9 2006 Taken together, these results indicate that minodronate suppresses PGF2alpha-stimulated VEGF synthesis at the point between PKC and Raf-1 in osteoblasts. Dinoprost 67-76 vascular endothelial growth factor A Mus musculus 88-92 15922088-0 2005 Tiludronate inhibits prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Dinoprost 21-42 vascular endothelial growth factor A Mus musculus 51-85 15922088-1 2005 We have previously reported that prostaglandin F2alpha (PGF2alpha) activates p44/p42 mitogen-activated protein (MAP) kinase through protein kinase C (PKC), resulting in the synthesis of vascular endothelial growth factor (VEGF) in osteoblast-like MC3T3-E1 cells, and that incadronate, a bisphosphonate, amplifies the VEGF synthesis. Dinoprost 33-54 vascular endothelial growth factor A Mus musculus 186-220 15922088-1 2005 We have previously reported that prostaglandin F2alpha (PGF2alpha) activates p44/p42 mitogen-activated protein (MAP) kinase through protein kinase C (PKC), resulting in the synthesis of vascular endothelial growth factor (VEGF) in osteoblast-like MC3T3-E1 cells, and that incadronate, a bisphosphonate, amplifies the VEGF synthesis. Dinoprost 33-54 vascular endothelial growth factor A Mus musculus 222-226 15922088-1 2005 We have previously reported that prostaglandin F2alpha (PGF2alpha) activates p44/p42 mitogen-activated protein (MAP) kinase through protein kinase C (PKC), resulting in the synthesis of vascular endothelial growth factor (VEGF) in osteoblast-like MC3T3-E1 cells, and that incadronate, a bisphosphonate, amplifies the VEGF synthesis. Dinoprost 33-54 vascular endothelial growth factor A Mus musculus 317-321 15922088-1 2005 We have previously reported that prostaglandin F2alpha (PGF2alpha) activates p44/p42 mitogen-activated protein (MAP) kinase through protein kinase C (PKC), resulting in the synthesis of vascular endothelial growth factor (VEGF) in osteoblast-like MC3T3-E1 cells, and that incadronate, a bisphosphonate, amplifies the VEGF synthesis. Dinoprost 56-65 vascular endothelial growth factor A Mus musculus 186-220 15922088-1 2005 We have previously reported that prostaglandin F2alpha (PGF2alpha) activates p44/p42 mitogen-activated protein (MAP) kinase through protein kinase C (PKC), resulting in the synthesis of vascular endothelial growth factor (VEGF) in osteoblast-like MC3T3-E1 cells, and that incadronate, a bisphosphonate, amplifies the VEGF synthesis. Dinoprost 56-65 vascular endothelial growth factor A Mus musculus 222-226 15922088-1 2005 We have previously reported that prostaglandin F2alpha (PGF2alpha) activates p44/p42 mitogen-activated protein (MAP) kinase through protein kinase C (PKC), resulting in the synthesis of vascular endothelial growth factor (VEGF) in osteoblast-like MC3T3-E1 cells, and that incadronate, a bisphosphonate, amplifies the VEGF synthesis. Dinoprost 56-65 vascular endothelial growth factor A Mus musculus 317-321 15922088-2 2005 In the present study, we investigated the effects of tiludronate and etidronate, other bisphosphonates, on the PGF2alpha-stimulated VEGF synthesis in these cells. Dinoprost 111-120 vascular endothelial growth factor A Mus musculus 132-136 15922088-3 2005 Tiludronate reduced the synthesis of VEGF induced by PGF2alpha. Dinoprost 53-62 vascular endothelial growth factor A Mus musculus 37-41 12646577-0 2003 Incadronate amplifies prostaglandin F2 alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Dinoprost 22-38 vascular endothelial growth factor A Mus musculus 53-87 12646577-3 2003 In the present study, we investigated the mechanism of vascular endothelial growth factor (VEGF) synthesis induced by PGF2 alpha and the effect of incadronate on the VEGF synthesis in these cells. Dinoprost 118-122 vascular endothelial growth factor A Mus musculus 55-89 12646577-3 2003 In the present study, we investigated the mechanism of vascular endothelial growth factor (VEGF) synthesis induced by PGF2 alpha and the effect of incadronate on the VEGF synthesis in these cells. Dinoprost 118-122 vascular endothelial growth factor A Mus musculus 91-95 12646577-4 2003 PGF2 alpha significantly stimulated the VEGF synthesis in a dose-dependent manner between 1 pm and 10 microm. Dinoprost 0-10 vascular endothelial growth factor A Mus musculus 40-44 12646577-6 2003 PGF2 alpha increased the levels of mRNA for VEGF. Dinoprost 0-10 vascular endothelial growth factor A Mus musculus 44-48 12646577-8 2003 Indomethacin, an inhibitor of cyclooxygenase, significantly reduced the PGF2 alpha-induced VEGF synthesis. Dinoprost 72-76 vascular endothelial growth factor A Mus musculus 91-95 12646577-9 2003 Bisindolylmaleimide, an inhibitor of PKC, reduced the PGF2 alpha-induced VEGF synthesis. Dinoprost 54-58 vascular endothelial growth factor A Mus musculus 73-77 12646577-10 2003 The VEGF synthesis induced by PGF2 alpha was significantly attenuated in the PKC down-regulated cells. Dinoprost 30-34 vascular endothelial growth factor A Mus musculus 4-8 12646577-12 2003 PD98059 or U0126, inhibitors of MEK, suppressed the VEGF synthesis induced by PGF2 alpha. Dinoprost 78-82 vascular endothelial growth factor A Mus musculus 52-56 12646577-14 2003 Incadronate enhanced the synthesis of VEGF induced by PGF2 alpha. Dinoprost 54-58 vascular endothelial growth factor A Mus musculus 38-42 12646577-16 2003 PD98059 suppressed the enhancement by incadronate of PGF2 alpha-induced VEGF synthesis. Dinoprost 53-57 vascular endothelial growth factor A Mus musculus 72-76 12646577-19 2003 These results strongly suggest that PGF2 alpha stimulates VEGF synthesis through the PKC-dependent activation of p44/p42 MAPK in osteoblasts and that the incadronate enhances the VEGF synthesis at the point between PKC and Raf-1. Dinoprost 36-40 vascular endothelial growth factor A Mus musculus 58-62